Chimeric Therapeutics Ltd (CHM) — Cash Flow-to-Debt Ratio
Chimeric Therapeutics Ltd (CHM) has a Cash Flow-to-Debt Ratio of -0.43x as of December 2025, meaning its operating cash flow of AU$-3.84 Million could theoretically repay 0% of its total liabilities (AU$8.96 Million) in one year. Explore how much of Chimeric Therapeutics Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Chimeric Therapeutics Ltd Cash Flow-to-Debt Ratio (2020–2025)
Historical debt coverage capacity for Chimeric Therapeutics Ltd across 6 annual periods. Also explore Chimeric Therapeutics Ltd (CHM) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Chimeric Therapeutics Ltd (2020–2025)
Year-by-year debt coverage analysis for Chimeric Therapeutics Ltd. For market capitalisation and broader financial context, see CHM stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.37x | AU$-7.28 Million | AU$19.60 Million | ▲ +36.9% |
| 2024 | -0.59x | AU$-7.54 Million | AU$12.80 Million | ▲ +39.7% |
| 2023 | -0.98x | AU$-16.32 Million | AU$16.71 Million | ▲ +31.9% |
| 2022 | -1.43x | AU$-13.15 Million | AU$9.17 Million | ▼ -84.4% |
| 2021 | -0.78x | AU$-8.84 Million | AU$11.37 Million | ▼ -46.3% |
| 2020 | -0.53x | AU$-34.01K | AU$64.01K | — |